Pulmotect, Inc.
  • Home
  • About Us
    • Our Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Approach
    • Overview
    • Our Science
    • Our Pipeline
    • Published Journal Articles
  • News
  • Contact Us

Pulmotect receives FDA approval to commence two Phase-2 trials targeting COVID-19

Posted on May 5, 2020 by Brenton Scott
Posted in Press Releases

Post navigation

Houston company working on possible COVID-19 treatment
Houston company testing drug to protect against COVID 19
Pulmotect Inc

3900 Essex Ln, Suite 575
Houston, TX 77027
Contact Us

© 2025
Pulmotect, Inc.